Late-onset clozapine-induced agranulocytosis in a patient with comorbid multiple sclerosis

General Hospital Psychiatry

Volumn 35, Issue 5, 2013, Pages

  Raveendranathan, Dhanya ^a   Sharma, Eesha ^a   Venkatasubramanian, Ganesan ^a   Rao, Mukund G ^a   Varambally, Shivarama ^a   Gangadhar, Bangalore N ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Agranulocytosis; Clozapine; Multiple sclerosis

Indexed keywords

AMISULPRIDE; BETA1A INTERFERON; CLOZAPINE; HALOPERIDOL; LITHIUM SALT; OLANZAPINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RISPERIDONE; STEROID;

ADULT; AGRANULOCYTOSIS; ARTICLE; BLOOD ANALYSIS; BONE MARROW BIOPSY; CASE REPORT; COMORBIDITY; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTENSION; LABORATORY TEST; LEUKOCYTE COUNT; MULTIPLE SCLEROSIS; NEUTROPHIL COUNT; PARANOID SCHIZOPHRENIA; PATIENT MONITORING; RETREATMENT; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION;

AGRANULOCYTOSIS; CLOZAPINE; MULTIPLE SCLEROSIS;

ADULT; AGRANULOCYTOSIS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; MULTIPLE SCLEROSIS; SCHIZOPHRENIA, PARANOID;

EID: 84884130402     PISSN: 01638343     EISSN: 18737714     Source Type: Journal    
DOI: 10.1016/j.genhosppsych.2012.07.001     Document Type: Article

References (12)

1. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988, 45:789-796.
2. Thompson A., Girishchandra B., Castle D., Orr K. Late onset neutropenia with clozapine. Can J Psychiatry 2004, 49:647-648.
3. Bhanji N.H., Margolese H.C., Chouinard G., Turnier L. Late-onset agranulocytosis in a patient with schizophrenia after 17 months of clozapine treatment. J Clin Psychopharmacol 2003, 23:522-523.
4. Sedky K., Shaughnessy R., Hughes T., Lippmann S. Clozapine-induced agranulocytosis after 11 years of treatment. Am J Psychiatry 2005, 162:814.
5. Tamam L., Kulan E., Ozpoyraz N. Late onset neutropenia during clozapine treatment. Psychiatry Clin Neurosci 2001, 55:547-548.
6. Young C.R., Bowers M.B., Mazure C.M. Management of the adverse effects of clozapine. Schizophr Bull 1998, 24:381-390.
7. Alvir J.M., Lieberman J.A. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994, 55(Suppl. B):137-138.
8. Lieberman J.A., Safferman A.Z. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992, 63:51-70.
9. Pisciotta A.V., Konings S.A. 51Cr release assay of clozapine-induced cytotoxicity: evidence for immunogenic mechanism. J Clin Psychiatry 1994, 55(Suppl. B):143-148.
10. Gerson S.L., Arce C., Meltzer H.Y. N-desmethylclozapine: a clozapine metabolite that suppresses haemopoiesis. Br J Haematol 1994, 86:555-561.
11. Schulte P.F., Cohen D., Bogers J.P., van Dijk D., Bakker B. A Dutch guideline for the use of clozapine. Aust N Z J Psychiatry 2010, 44:1055-1056.
12. Drew L.R. Controls on clozapine must be reviewed. Aust N Z J Psychiatry 2010, 44:490.